Document:

License and Supply Agreement

 Exhibit 10.14 

LICENSE AND SUPPLY AGREEMENT 

This License and Supply Agreement (“Agreement”) is effective as of the
13th day of May, 2010 (the “Effective
Date”), between BG Medicine, Inc., a Delaware corporation with offices located at 610N Lincoln Street, Waltham, MA 02451 (“BGM”), and Laboratory Corporation of America Holdings, a Delaware corporation with offices located
at 531 South Spring Street, Burlington, NC 27215 (“LabCorp”). 
 WHEREAS, BGM has developed an assay for
measuring Galectin-3 levels in a human specimen, which has been shown to provide clinically useful information that could be used by physicians as an aid in the stratification of patients diagnosed with heart failure, among other potential clinical
indications; and 
 WHEREAS, BGM has submitted a 510(k) application to obtain clearance from the FDA to sell the test in
the United States; and 
 WHEREAS, LabCorp is engaged in the business of providing laboratory testing services; and

 WHEREAS, LabCorp desires to license certain rights from BGM and purchase kits from BGM for the performance of
BGM’s Galectin-3 assay following FDA approval of the assay, and BGM desires to grant such license and sell such kits to LabCorp in accordance with the terms and conditions of this Agreement. 

NOW THEREFORE, LabCorp and BGM hereby agree as follows: 

1. Definitions. For purposes of this Agreement, the terms below shall have the meanings set forth below. Additional terms are defined above and
throughout the Agreement. 
 “ACS In-License Agreement” means the Product License and Collaboration Agreement
dated May 4, 2007, entered into between BGM, ACS Biomarker B.V. i.o., BioMedbooster B.V., Yigal Pinto, Mat Daemen, Tilman Hackeng and Marcel Kannekens. 

“Affiliate” means, with respect to a party to this Agreement, any current or future Entity which controls, is controlled
by, or is under common control with such party. For purposes of this definition only, “control” means direct or indirect ownership of at least fifty percent (50%) of the shares of the subject Entity entitled to vote in the election of
directors (or, in the case of an Entity that is not a corporation, for the election of the corresponding managing authority). 

“AMA” means the American Medical Association. 

“Automated Test” means a version of the Test which is performed essentially without handheld pipettors, and with little
or no technologist intervention to move the samples through the steps of the protocol. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

1 

 “Automated Test Kit” means a Kit for performing the Automated Test.

 “Change of Control” means a transaction or event (or series of related transactions or events) as a result
of which the holders of the outstanding voting stock of a party as of the Effective Date cease to own a majority of the outstanding voting stock of such party, excluding an initial underwritten public offering by BGM of its securities under an
effective registration statement under the Securities Act of 1933. 
 “Clinical Lab” means any Entity engaged
in the business of providing clinical laboratory products and/or services. 
 “CMO” means any Entity with which
BGM contracts for the manufacture of Manual Test Kits. 
 “Commercial Launch Date” means the date on which the
Test is first made generally available to physicians or other third party medical providers (as a Kit or service) for use in a clinical setting after FDA Approval (specifically excluding performance of Tests in connection with research or clinical
trials). There will be a different Commercial Launch Dates for the Manual Test and Automated Test. 
 “Desired [***]
Change” means an [***] for galectin-3 testing (that would include the Manual Test) with a Medicare national limitation amount (“NLA”) equal to or greater than [***]. 

“Entity” means a person, corporation, partnership, association, limited liability company, unincorporated organization,
firm, or other entity. 
 “FDA” means the United States Food and Drug Administration or any successor agency
thereto. 
 “FDA Approval” means final approval or clearance by the FDA through a premarket approval
application (PMA), 510(k) premarket notification (PMN), or other applicable regulatory pathways which are now or may become available to market and sell the Testing Services for commercial purposes in the United States for use with regard to humans.
For purposes of clarification, FDA Approval shall not include a laboratory’s provision of services pursuant to its CLIA license. 

“Galectin-3” means the protein known as Galectin-3. 

“GMP” shall mean the current Good Manufacturing Practice regulations and the Quality System Regulations promulgated by
the FDA, including 21 C.F.R. Part 820 et seq., as such regulations may be amended from time to time, and such equivalent regulations or standards of countries outside the United States as may be applicable to activities conducted hereunder.

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

2 

 “Kit” means an in vitro diagnostic medical device, as defined in regulation
at 21 C.F.R. § 809.3(a), that is in a kit form and that requires FDA Approval, which allows the Licensed Technology to be used to perform the Test. 

“Kit Price” means (i) [***] Dollars ($[***]) per Manual Test Kit until the Desired [***] Change has been approved
by the [***], and (ii) [***] Dollars ($[***]) per Manual Test Kit after the Desired [***] Change has been approved by the [***]. 

“Licensed Technology” means any and all Technology related to the Manual Test that is created, developed, owned,
licensed, controlled, or otherwise possessed by BGM at any time during the Term, and for which BGM has Licensing Control, including without limitation (i) the patents and patent applications listed on Exhibit A, and (ii) all trade
secrets, know-how, and processes relating to the Test. 
 “Licensing Control” means, with respect to any
Technology, possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise, to grant a license, sublicense or other right to or under, such Technology, as contemplated by this Agreement without violating the
terms of any agreement with a third party. 
 “Manual Test” means a version of the Test which is performed
using handheld pipettors, with technologist intervention to move the samples through the steps of the testing protocol. 

“Manual Test Kit” means a Kit for performing the Manual Test, as currently described on Exhibit B attached
hereto. For purposes of clarification, the parties acknowledge that to the extent that Exhibit B states that the Manual Test is “For Research Use Only” and “Not for Use in Diagnostic Procedures”, these statements will not
apply after FDA Approval has been obtained. Upon FDA Approval of the Manual Test, Exhibit B will be replaced by the actual package insert at that time. 

“Permitted Licensee” means an Entity that is not a Restricted Licensee. 

“Rebate Period” means Rebate Period 1, Rebate Period 2, or Rebate Period 3, as applicable. 

“Rebate Period 1” means the period beginning on the Commercial Launch Date for the Automated Test and ending on the one
(1) year anniversary of such Commercial Launch Date. 
 “Rebate Period 2” means the period beginning on
the one (1) year anniversary of the Commercial Launch Date for the Automated Test and ending on the two (2) year anniversary of such Commercial Launch Date. 

“Rebate Period 3” means the period beginning on the two (2) year anniversary of the Commercial Launch Date for the
Automated Test and ending on the three (3) year anniversary of such Commercial Launch Date. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

3 

 “Regulatory Authority” means any governmental authority with jurisdiction
over the manufacture, distribution, use, and marketing of in vitro diagnostics and/or new drug products intended for human use, including the FDA. 

“Restricted Licensee” means any Entity which has an [***] from third-party [***] in the United States (including all
such [***] in the United States of its Affiliates) which exceeds [***] Dollars ($[***] in its most recently ended fiscal year, except for the [***] listed on Exhibit C attached hereto. The determination of an Entity’s [***] for purposes
of this definition shall be made based on the best information available to the parties, including without limitation public filings, industry reports, or representations made by such Entity. 

“Sales Threshold” means the quantity of Automated Tests which must be sold in order for LabCorp to be entitled to a
Rebate, as indicated in the table in Section 5.1. 
 “Semi-Exclusive Period” means the period beginning on
the Effective Date and ending on the three (3) year anniversary of the Commercial Launch Date for the Manual Test. 

“Specifications” means the specifications and descriptions for the Manual Test Kit set forth in the package insert and
the manufacturer specifications. 
 “Technology” means any (i) inventions (whether or not patentable),
know-how, works of authorship, technology, techniques, processes, methods, developments, ideas, concepts, discoveries, designs, algorithms, models, formulations, improvements, protocols, data and proprietary information; and (ii) patents,
copyrights, trademarks, service marks, trade secret, trade dress, or other intellectual property rights associated with the foregoing, including without limitation any applications (whether provisional, PCT or otherwise), divisionals, continuations,
continuations-in-part, reissues, substitutions, re-examinations, renewals, re-registrations, refilings, extensions and modifications relating to any of the foregoing. 

“Term” means the period beginning on the Effective Date and ending upon expiration or termination of this Agreement.

 “Territory” means the United States of America, Canada and the United Arab Emirates, and each of their
territories. 
 “Test” means an assay that measures Galectin-3 in a human specimen by enzyme-linked
immunosorbent assay (ELISA) on a microtiter plate platform, as such assay may be improved or otherwise modified from time to time during the Term. Initially, the parties believe that the Test will likely be marketed for use in conjunction with
clinical evaluation as an aid in the stratification of patients diagnosed with heart failure. However, the parties anticipate that the Test may subsequently be marketed for other indications or applications, including without limitation for use in
conjunction with monitoring patients who have suffered a heart attack. The parties acknowledge that the “Test,” for purposes of this Agreement, includes all such potential indications or applications for the Test. 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

4 

 “Testing Service” means the performance of the Manual Test for third
parties. 
 2. License to Licensed Technology. 

2.1 Grant and Scope of License. BGM hereby grants to LabCorp and each of its Affiliates a license to use the Licensed Technology
to perform Manual Tests and market, offer for sale, sell, import, export and otherwise commercialize the Testing Services in the Territory. 

2.2 Semi-Exclusivity. The license granted under Section 2.1 shall be (i) Semi-Exclusive (as defined below) to LabCorp
and its Affiliates in the U.S. during the Semi-Exclusive Period, (ii) non-exclusive in the U.S. for the remainder of the Term after the Semi-Exclusive Period, and (iii) non-exclusive in Canada and the United Arab Emirates for the entire
Term. For purposes of this Agreement, “Semi-Exclusive” means BGM shall not license or otherwise transfer or provide the Licensed Technology to any Restricted Licensees for use with Manual Tests in the United States, or authorize or
permit use of the Licensed Technology by any Restricted Licensees under the terms of any agreement with Restricted Licensee (whether through a covenant not to sue or otherwise) in connection with Manual Tests in the United States, during the
Semi-Exclusive Period. In addition, during the Semi-Exclusive Period, to the extent BGM licenses or otherwise transfers or provides the Licensed Technology to any Permitted Licensee, or authorizes or permits use of the Licensed Technology by a
Permitted Licensee, BGM’s agreement with such Permitted Licensee shall prohibit such Permitted Licensee from (a) sublicensing or otherwise transferring or providing the Licensed Technology to any Restricted Licensees for use with Manual
Tests in the United States, or (b) authorizing or permitting use of the Licensed Technology by any Restricted Licensees in connection with Manual Tests in the United States. In the event the inclusion of the U.S. territory in the limitation of
the Semi-Exclusive grant or the Semi-Exclusive Period of the license granted hereunder is limited by action, laws or regulations of any government, the license granted shall not terminate, but shall remain Semi-Exclusive to the extent permitted by
such government action and shall become non-exclusive to the extent necessary to conform with applicable laws and regulations. 

2.3 Additional Technology. Any Technology that may be useful in connection with the performance of Manual Tests and that is
created, developed, owned, licensed, controlled, or otherwise possessed by BGM and for which BGM has Licensing Control at any time during the Term (including without limitation improvements, derivative works, additions, enhancements, updates or
other modifications to the Licensed Technology, and any new Technology which relates to, is dependent on, or includes or utilizes any portion of the Licensed Technology) shall automatically be included within the definition of “Licensed
Technology” and the license granted in Section 2.1 for purposes of this Agreement (and any patents or patent applications relating to such Technology shall automatically be added to Exhibit A) without additional charge to LabCorp
and its Affiliates. BGM shall promptly notify LabCorp in writing of all such Technology. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

5 

 2.4 Technology Transfer. BGM agrees to provide any technical information or know- how
possessed by BGM and reasonably requested by LabCorp for its use in the performance of Manual Tests. 
 2.5 ACS In-License
Agreement. BGM shall duly and punctually perform all of its obligations under the ACS In-License Agreement. BGM shall not modify or amend the ACS In-License Agreement in any manner that will adversely affect LabCorp. 

3. Supply of Manual Test Kits. 

3.1 Purchase Orders. LabCorp will submit to BGM purchase orders for Manual Test Kits from time to time. All purchase orders shall
specify the type and quantity of Manual Test Kits being ordered, the requested delivery date, and the requested delivery location, which shall be in the Territory. 

3.2 Acceptance of Orders. Upon receipt of each purchase order, BGM shall, within [***] ([***]) [***], provide written confirmation
to LabCorp of receipt of the purchase order, and notify LabCorp that it either accepts the purchase order or rejects it. However, BGM shall not reject any purchase order from LabCorp which gives BGM at least [***] ([***])[***] lead time from the
date of BGM’s receipt of the purchase order to the requested delivery date (the “Required Lead Time”). In cases in which LabCorp does not provide the Required Lead Time, BGM shall use commercially reasonable efforts to accept
and fill such order but may reject such order if it is unable to fill it within the given lead time, in which case BGM shall propose an alternative date of delivery along with its rejection of the purchase order. After receipt of a notice of
rejection of an order containing the alternative date of delivery, LabCorp may either accept the alternative date of delivery or LabCorp may cancel its order. BGM agrees to supply the Manual Test Kits to LabCorp in accordance with the terms of each
accepted purchase order. 
 3.3 Changes. BGM agrees to use reasonable efforts to accommodate any changes to a particular
purchase order requested by LabCorp. Any such changes shall not be effective without the written agreement of both parties. 

3.4 Delivery Schedule. BGM acknowledges that time is of the essence with respect to delivery of each shipment of Manual Test Kits
within [***] ([***]) business days of the delivery date set forth in each accepted purchase order (the “Delivery Window”). Without limiting LabCorp’s rights and remedies, if, for any reason, BGM cannot or will not deliver any
Manual Test Kits within the Delivery Window, then BGM shall immediately notify LabCorp and LabCorp may, in its discretion, terminate that purchase order without liability. 

3.5 Labeling; Packaging. All Manual Test Kits shall be labeled, packaged and shipped in accordance with applicable law.

 3.6 Shipping Charges; Risk of Loss. All shipments shall be made FOB site of manufacture (which shall be within the
United States unless otherwise agreed by LabCorp). LabCorp shall designate the carrier for shipment. BGM shall bear all risk of loss until such time as delivery is made to the carrier for shipment to LabCorp. 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

6 

 3.7 Quality Control Testing. All production batches of Manual Test Kits shall be
tested in accordance with appropriate quality control testing procedures prior to shipment to LabCorp, and Manual Test Kits failing such testing shall not be shipped to LabCorp. 

3.8 Inventory/Capacity. BGM shall use commercially reasonable efforts to maintain, or require its CMOs to maintain, a sufficient
inventory of all materials and manufacturing capacity needed to manufacture the Manual Test Kits in the quantities ordered by LabCorp, assuming the Required Lead Time is provided by LabCorp. BGM shall establish commercially reasonable plans that can
be implemented in the event one or more of its suppliers fails to provide materials required by BGM to supply LabCorp with Manual Test Kits, to arrange for alternative supply sources. 

3.9 Applicable Terms. Except for the information to be contained in purchase orders (as described in Section 3.1) and the
terms of this Agreement, no other terms of either party shall apply to the purchase and sale of Manual Test Kits unless expressly agreed upon by the parties in writing. For example, any standard terms and conditions of sale contained in or attached
to any purchase order, order confirmation or invoice shall not apply. 
 3.10 Supply to Affiliates. If any Affiliate of
LabCorp located in the Territory desires to purchase Manual Test Kits from BGM under the terms of this Agreement, then BGM shall provide such Affiliate with all of the benefits hereof and treat such Affiliate as LabCorp for the purposes of this
Agreement and such Affiliates shall have all the obligations of LabCorp hereunder. LabCorp unconditionally guarantees all of the obligations contained in this Agreement of its Affiliates purchasing Manual Test Kits from BGM pursuant to this
Agreement. 
 3.11 Semi-Exclusivity. BGM agrees that it shall not sell, distribute, supply or otherwise provide Manual
Test Kits (or any materials or components thereof) to any Restricted Licensees for use in the United States during the Semi-exclusive Period. In addition, during the Semi-Exclusive Period, to the extent BGM sells, distributes, supplies or otherwise
provides Manual Test Kits (or any materials or components thereof) to any Permitted Licensees for use in the United States, BGM’s agreement with such Permitted Licensees shall prohibit such Permitted Licensees from reselling, distributing,
supplying or otherwise providing them to any Restricted Licensees. The parties acknowledge that an Entity could change its status from a Permitted Licensee to a Restricted Licensee over time due to one or more mergers, consolidations,
reorganizations, or acquisitions with, of, or by other Entities (“M&A Transactions”), and BGM agrees that it shall monitor the impact of M&A Transactions on the status of any Permitted Licensees which have been granted a license
(or other permission or authorization) to use the Licensed Technology with Manual Tests and which are being supplied Kits. In the event a Permitted Licensee becomes a Restricted Licensee during the Semi-Exclusive Period due to M&A Transactions,
BGM shall immediately terminate such license or other permission or authorization, and immediately cease the supply of Manual Test Kits, unless LabCorp agrees that 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

7 

 
BGM may add such Entity to Exhibit C. BGM shall include terms in all of its agreements with Permitted Licensees which allow BGM to take the foregoing action. In the event an Entity
supplied and licensed by BGM as a Permitted Licensee subsequently becomes a Restricted Licensee without the occurrence of any M&A Transactions (i.e., based solely on natural growth of its gross revenues), then such Entity shall retain its status
as a Permitted Licensee. 
 4. Payments to BGM. 

4.1 Prices. LabCorp agrees to pay the Kit Price for each Manual Test Kit purchased by LabCorp and its Affiliates, subject to any
adjustments under Section 4.2 below. 
 4.2 Adjustments to Kit Price. The Kit Price shall be [***], subject to any
adjustments pursuant to this Section 4.2. 
 a. Minimum Number of Tests Per Kit. The parties acknowledge that the
Kit Price was established based on the assumption that each Manual Test Kit will be capable of being used by LabCorp or its Affiliates to perform at least [***] ([***]) Manual Tests. In the event that BGM supplies Manual Test Kits that are not
capable of performing at least [***] ([***]) Manual Tests per Manual Test Kit, then the parties agree to negotiate in good faith on an equitable adjustment to the Kit Price. 

b. Most Favored Nation Pricing. The Kit Price payable by LabCorp and its Affiliates for Manual Test Kits shall be no less
favorable than the price charged by BGM to any third parties in the U.S. for Manual Test Kits other than (i) sales of Manual Test Kits to agencies of the U.S. federal government, or (ii) sales of Manual Test Kits to third parties solely
for the purpose of conducting research in collaboration with BGM. In the event BGM offers a third party (other than those excluded above) more favorable pricing for Manual Test Kits, BGM shall immediately notify LabCorp in writing and LabCorp may
accept such more favorable pricing in lieu of the Kit Price established under this Agreement by providing notice to BGM. 
 4.3
No Other Payments. Except as specified in this Section 4, no other payments shall be due from LabCorp or its Affiliates in exchange for the rights granted or obligations assumed by BGM under this Agreement. 

4.4 Preferred Exchange of Documents Electronically. BGM and LabCorp acknowledge the efficiency of automated invoicing and payment.
Both parties desire to automate certain operations for purchase and sale transactions (“Transactions”), by transmitting and receiving, documents electronically (hereinafter called “Documents”) in substitution for
conventional paper-based documents. Examples of Documents which may be transmitted include: purchase orders; acknowledgments; modifications to purchase orders; ship notices; invoices; schedule changes; and change orders. BGM and LabCorp acknowledge
that such Transactions are not rendered legally invalid or unenforceable solely by virtue of such electronic transmission or reception. Each party shall, at its own expense, provide and maintain the equipment, software and services necessary to
effectively and reliably transmit and receive Documents. Any signed Document transmitted through e-commerce shall constitute an 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

8 

 
“original” when printed from electronic files or records established and maintained in the normal course of business. The parties further agree not to contest the validity or
enforceability of signed Documents under the provisions of any applicable law relating to whether certain agreements are to be in writing and signed by the party to be bound thereby. 

4.5 Invoicing; Payment Terms and Taxes. BGM will provide an invoice to LabCorp for all Manual Test Kits ordered and shipped to
LabCorp or its Affiliates, which shall be payable by LabCorp within forty-five (45) days after the date of LabCorp’s receipt of the invoice. All BGM invoices must be submitted to LabCorp within ninety (90) days of the close of the
applicable month in which Manual Test Kits were shipped to LabCorp or its Affiliates. LabCorp shall have no obligation to pay for invoices submitted beyond this ninety (90) day period. LabCorp is taxable based on the shipment destination and
all applicable local/state taxes are the responsibility of LabCorp. In those states where BGM collects local/state sales taxes, BGM will add these taxes to the invoices and remit to the appropriate taxing authority. If BGM is unable to comply with
the e-commerce provisions of Section 4.4, invoices shall be mailed to LabCorp at the following address: 
 SEND INVOICES
TO: 
 Laboratory Corporation of America Holdings 

Accounts Payable Department 

Caller 2280 

Burlington, North Carolina 27216-2280 

5. Automated Tests. 

5.1 Rebates to LabCorp. BGM acknowledges that the commitment of resources made by LabCorp and its Affiliates under this Agreement
in connection with its performance, marketing and sale of the Testing Service will be beneficial to BGM in building the market for the Test once the Automated Test is available. Therefore, if the aggregate number of Automated Tests which are capable
of being performed in the U.S. using Automated Test Kits sold (whether sold by BGM or its suppliers, distributors, sales representatives, licensees, agents, or other business partners) in any Rebate Period (the “Total Sales Volume”)
exceeds the Sales Threshold designated below, then BGM agrees to pay LabCorp an amount equal to [***] ($[***]) multiplied by the Total Sales Volume (the “Rebate”). The Rebate shall be paid by BGM to LabCorp within [***] ([***]) days
after the end of each Rebate Period, along with a written report indicating the Total Sales Volume for the applicable Rebate Period and the computation of the Rebate. The parties acknowledge that the rebate provided pursuant to this section is a
discount for purposes of the “Safe Harbor” regulations set forth in 42 C.F.R. § 1001.952(h), and LabCorp shall, in accordance with such “Safe Harbor” regulations, fully and accurately account for, disclose and provide
information to the Federal government and state agencies with responsibilities for Federal healthcare programs upon request concerning the amount received as discounts hereunder. 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

9 

			
	 Rebate Period
	  	 Sales Threshold

	Rebate Period 1	  	[***] Automated Tests
	Rebate Period 2	  	[***] Automated Tests
	Rebate Period 3	  	[***] Automated Tests

 For example, if,
in Rebate Period 1, BGM and its business partners were to sell [***] ([***]) Automated Test Kits for Automated Tests to be performed in the U.S., and each Automated Test Kit was capable of performing [***] ([***])
Automated Tests, this would constitute a total of [***] ([***]) Automated Tests, and BGM would pay LabCorp [***] Dollars ($[***]). 

5.2 Supply of Automated Test Kits to LabCorp. To the extent BGM enters into agreements with third parties after the Effective Date
which permit such third parties to manufacture, supply or distribute Automated Test Kits, BGM shall require such third parties (the “Suppliers”) to agree to supply such Automated Test Kits to LabCorp and its Affiliates [***]. BGM
agrees to use reasonable efforts to enforce this provision in the event of a breach by a Supplier. 
 6. Support and Assistance.

 6.1 Support to be Provided by BGM. BGM agrees to provide the following clinical market development resources, programs
and assistance as reasonably requested by LabCorp for the Testing Services (at no additional cost to LabCorp), as well as any other resources, programs and assistance as the parties agree upon: 

a. BGM will use commercially reasonable efforts to obtain FDA Approval for the Manual Test; 

b. BGM will manage clinical studies it performs concerning the Test, clinical publications relating to the Test, and maintain the
supporting data and other sources of proof concerning the safety, accuracy and efficacy of the Test; 
 c. BGM will use
commercially reasonable efforts to maintain relationships with key opinion leaders in the field associated with the Test; 
 d.
BGM will use commercially reasonable efforts to manage and fund society and clinical speakers bureaus which may be beneficial for the Test; 

e. BGM will use commercially reasonable efforts to offer CME and other medical education programs relating to the Test; 

f. BGM will use commercially reasonable efforts to provide field sales support for the Test in coordination with LabCorp; 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

10 

 g. BGM will provide commercially reasonable support to LabCorp to help establish appropriate
reimbursement by insurance companies and other third party payors for the Test; 
 h. BGM will use commercially reasonable
efforts to obtain the Desired [***] Change, (the parties currently anticipate that [***] will be used initially for purposes of [***] for the Manual Test); and 

i. BGM will supply LabCorp and its Affiliates with marketing and promotional information for the Test for inclusion by LabCorp in the
materials created by LabCorp pursuant to Section 6.2(c). 
 6.2 Support to be Provided by LabCorp. LabCorp agrees to
provide the following marketing support and market education assistance during the Term of this Agreement (at no additional cost to BGM): 

a. LabCorp will determine which of its testing sites will be used for the Test and perform the necessary laboratory analytical validation
studies; 
 b. LabCorp will establish a specific order code for the Test and use commercially reasonable efforts to make its
Testing Service available to the U.S. market within forty-five (45) days after FDA Approval of the Manual Test; 
 c.
LabCorp will create and distribute promotional materials for the Test to LabCorp clients via LabCorp couriers, including without limitation (i) a [***], and (ii) a technical document (created and reviewed with assistance from BGM)
describing Galectin-3 and the Test in more detail (anticipated to be 4-8 pages); 
 d. LabCorp will train its sales and service
representatives (including without limitation communicating the core messages and value proposition for the Test) to enable them to sell the Testing Service by calling on relevant physician segments; 

e. LabCorp will [***] to [***] who have [***]; 

f. LabCorp will [***] and is [***] to [***] for use with [***]; 

g. LabCorp will cooperate in good faith with BGM in the participation and promotion (with BGM representatives) of a reasonable number of
BGM-funded events (including without limitation “Lunch and Learns”, grand rounds, and professional/medical seminars), provided LabCorp receives reasonable prior notice of such events; 

h. LabCorp will seek appropriate reimbursement for the Test by insurance companies and other third party payors; and 

i. LabCorp will [***] with a [***] of the [***] for [***]. 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

11 

 7. Kit Quality, Warranties, and Legal Standards. 

7.1 BGM Warranties. BGM represents, warrants and covenants to LabCorp that: 

a. All Manual Test Kits shall be free from material defects when shipped to LabCorp and its Affiliates and shall conform to their
Specifications for a minimum shelf life of the longer of (i) [***] ([***]) [***] from the date of delivery, or (ii) [***] ([***])[***] from the date of manufacture; 

b. In the event LabCorp and its Affiliates’ Test repeat rate attributable to Manual Test Kit defects (but not attributable to
LabCorp or its Affiliates’ personnel human error or equipment error) is greater than [***] percent ([***]%) for any cumulative [***] ([***])[***]time period, BGM will credit or reimburse LabCorp (in LabCorp’s discretion) for the cost of
[***] defective Manual Test Kits. For purposes of this Section 7.1.b., repeat rates shall be calculated by confirmed Manual Test Kit failures as defined by instrument error codes or other documentation provided by LabCorp, including without
limitation quality control records and performance standards documentation; 
 c. BGM will convey to LabCorp and its Affiliates
good and full title to all Manual Test Kits delivered, free and clear of any security interests, liens, claims or encumbrances; 

d. BGM’s obligations and responsibilities under this Agreement (including without limitation the manufacture and supply of the
Manual Test Kits) will be performed in a competent manner in conformance with the standard of care usually and reasonably expected in the performance of such activities in the industry, and in compliance with applicable federal, state and local
laws, rules and regulations, as interpreted and enforced by Regulatory Authorities, and specifically in accordance with then-current GMP; 

e. To BGM’s knowledge, neither BGM nor any of its employees or agents rendering services pursuant to this Agreement is under
investigation by any Regulatory Authority, including the FDA, for activities that could form the basis of a debarment action or is presently debarred pursuant to the Generic Drug Enforcement Act of 1992, 21 U.S.C. § 335a, or any other similar
law of any Regulatory Authority; and BGM shall notify LabCorp promptly upon any learning of any inquiry concerning or the commencement of any such investigation or proceeding involving BGM or any person or entity related to or involved in BGM’s
performance of its obligations under this Agreement; 
 f. If any Regulatory Authority conducts or gives notice to BGM of its
intent with respect to any activities under this Agreement to conduct an inspection at any BGM facility where the Manual Test Kits are manufactured, packaged, labeled, stored, or used or take any other regulatory action related to any of BGM’s
activities under this Agreement, or if BGM becomes aware of any such governmental inspection or other regulatory activity, BGM shall promptly give LabCorp notice thereof, including all information known to BGM pertaining to any such inspections or
actions, unless and only to the extent restricted by the governmental or Regulatory Authority or applicable law; 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

12 

 g. BGM’s personnel and consultants have, and shall have, all training, licenses,
approvals, certifications, immunizations, equipment and information to the extent required by law, including specifically 21 C.F.R. Part 820 (to the extent applicable), and consistent with the standard of care in the industry, including those
actions reasonably necessary for safely and properly performing the obligations under this Agreement, and BGM will use commercially reasonable efforts to ensure that all such training, licenses, approvals, certifications, immunizations, equipment
and information are properly maintained throughout the conduct of BGM’s activities under this Agreement; 
 h. BGM is and
will remain in compliance with all applicable regulatory and legal requirements, as interpreted and enforced by Regulatory Authorities, including but not limited to registration and listing requirements under 21 C.F.R. Part 807 (to the extent
applicable), and the Quality System Regulations under 21 C.F.R. Part 820; 
 i. Neither BGM nor, to its knowledge, any of its
personnel, have been involved in an investigation or in research that was terminated, as the term “termination” is used in 21 C.F.R. § 812.3(q), nor, to BGM’s knowledge, have they been subjected to any restrictions or sanctions
related to allegations of research or professional misconduct; 
 j. None of the Manual Test Kits supplied by BGM shall be
adulterated or misbranded (within the meaning of the U.S. Food Drug and Cosmetic Act, as amended, 21 U.S.C. 301 et. seq., and the regulations promulgated thereunder) when shipped by BGM to LabCorp; 

k. BGM is the exclusive owner or exclusive licensee of the patent rights listed on Exhibit A and has sufficient rights to license
the Licensed Technology to LabCorp and its Affiliates as specified in this Agreement; 
 l. LabCorp and its Affiliates’
practice of the Licensed Technology, use of the Manual Test Kits to perform the Tests, and sale of the Testing Services is to the best of BGM’s knowledge free of any infringement of any third party patents or violation of any other third party
intellectual property or proprietary rights; 
 m. As of the Effective Date, BGM has not granted any licenses or covenants
not-to-sue to any Restricted Licensees which would allow the use of the Licensed Technology to perform Manual Tests in the U.S.; 

n. This Agreement, to the best of its knowledge, does not contravene or constitute a violation by BGM of any applicable laws, rules,
regulations or orders, or a default of any agreement, commitment, or instrument to which BGM is bound; 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

13 

 o. BGM has provided to LabCorp an accurate, current, and complete copy of the ACS In-License
Agreement (as amended to date), except for certain financial terms which were redacted; and 
 p. The ACS In-License Agreement
is presently valid and in full force and effect, BGM has duly and punctually performed all of its obligations under such agreement (including without limitation paid all royalties and other payments heretofore due and payable), and BGM is not in
default of such agreement. 
 7.2 Records. BGM shall, at all times, keep accurate records with respect to Manual Test
Kits produced and sold to LabCorp pursuant to this Agreement, as required by applicable law, including without limitation GMP. 

7.3 LabCorp Warranties. LabCorp represents, warrants and covenants to BGM that: 

a. LabCorp’s obligations and responsibilities under this Agreement (including without limitation the performance of Manual Tests)
will be performed in compliance with applicable federal, state and local laws, rules and regulations, as interpreted and enforced by Regulatory Authorities; and 

b. LabCorp’s personnel and consultants have, and shall have, all training, licenses, approvals, certifications, immunizations,
equipment and information to the extent required by law, and consistent with the standard of care in the industry, including those actions reasonably necessary for safely and properly performing the obligations under this Agreement, and LabCorp will
use commercially reasonable efforts to ensure that all such training, licenses, approvals, certifications, immunizations, equipment and information are properly maintained throughout the conduct of LabCorp’s activities under this Agreement.

 8. Term; Termination. 

8.1 Term. This Agreement shall commence as of the Effective Date and, unless earlier terminated pursuant to the terms of this
Agreement, shall continue until the later of (a) the five (5) year anniversary of the Effective Date, or (b) the end of the Semi-Exclusive Period. Upon expiration of the foregoing period, this Agreement shall automatically terminate
unless extended by mutual written agreement of the parties. 
 8.2 Termination for Breach. This Agreement may be
terminated upon sixty (60) days prior written notice by either party for failure of the other party to comply with the terms of this Agreement (with the notice including a reasonable description of such failure), unless the party in default
remedies its failure within such sixty (60) day notice period. 
 8.3 Termination for Change of Control. BGM shall
notify LabCorp in writing immediately in the event of a Change of Control of BGM. LabCorp may terminate this Agreement immediately upon written notice in the event of a Change of Control of BGM to a competitor of LabCorp. 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

14 

 8.4 Termination for Convenience. LabCorp may terminate this Agreement at any time,
for any reason, upon one hundred twenty (120) days prior written notice to BGM. 
 8.5 Effect of Termination. Upon
the expiration or termination of this Agreement for any reason, (i) LabCorp shall be responsible for the payment of all issued and outstanding invoices for Manual Test Kits delivered and accepted as of the effective date of expiration or
termination hereof and any Manual Test Kits delivered and accepted under subsection (ii) hereof; (ii) BGM shall complete delivery of Manual Test Kits under all purchase orders then existing according to the terms of this Agreement unless
LabCorp notifies BGM that it is canceling some or all pending orders; (iii) each party shall promptly return any confidential information of the other Party (including without limitation all copies) except for one copy which may be retained
solely for archival/legal purposes; and (iv) the provisions of Sections 5.1 (unless LabCorp terminates this Agreement for convenience under Section 8.4), 7.1, 7.2, 7.3, 8.5, 9, 10, 11.1 (for suits initiated prior to expiration or
termination), 12, 13.1, 13.3, 14.1, 14.2, 14.4, 14.5, 14.7 and 14.8, as well as any other obligations which by their terms continue after expiration or termination of this Agreement, shall survive the expiration or termination of this Agreement for
any reason and remain binding upon the parties. Notwithstanding the expiration or termination of this Agreement for any reason, LabCorp and its Affiliates shall be permitted, following such termination, to use any Manual Test Kits it has already
purchased to perform Tests and sell the Testing Services. 
 9. Confidentiality. The parties acknowledge that they may exchange
confidential or proprietary information as a result of this Agreement. For example, all information contained in LabCorp’s purchase orders, LabCorp’s geographical distribution of Tests, and LabCorp’s marketing and sales plans shall be
considered confidential information of LabCorp under this Agreement. Each party agrees that, during the term of this Agreement and thereafter, it shall not, directly or indirectly, (i) use the other party’s confidential or proprietary
information for any reason other than to perform its obligations or exercise its rights under this Agreement, or (ii) disclose or otherwise make available the other party’s confidential or proprietary information to any third Parties,
except in either case as authorized by such other party in writing. 
 10. Indemnification. 

10.1 Indemnification by BGM. BGM agrees to indemnify, defend, and hold harmless LabCorp, its Affiliates, and their respective
employees, officers, directors, agents, successors, and assigns from and against any and all liabilities, obligations, losses, fines, costs, penalties, assessments, deficiencies, demands, actions, suits, proceedings, judgments, expenses or damages
of any nature (including without limitation attorneys’ fees) resulting from claims of third parties arising from or relating to (i) any breach of this Agreement by BGM (including without limitation breach of any representations,
warranties, covenants or obligations of BGM herein), (ii) any negligence or intentionally harmful misconduct of BGM, (iii) the Manual Test Kits (or LabCorp and its Affiliates use thereof to perform Tests and sell the Testing Services as
contemplated by this Agreement) infringing upon or otherwise violating any third party patent, copyright, trade secret, or other proprietary rights, (iv) any misrepresentations made by BGM’s

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

15 

 
field representatives or other employees or agents to third parties concerning the Test or Testing Services, or (v) LabCorp and/or its Affiliates’ proper use of any Manual Test Kits
supplied by BGM under this Agreement. However, the foregoing rights to indemnity shall not apply to the extent that such claim results from LabCorp’s negligence or intentionally harmful misconduct, LabCorp’s breach of this Agreement, or
from the modification or improper handling, storage or use of any Manual Test Kit by LabCorp or a third party outside of BGM’s control or without BGM’s permission or any incorrect reporting of results from the performance of Manual Tests.
In the event of a lawsuit or other action in connection with which LabCorp is seeking indemnification from BGM hereunder, LabCorp agrees to give timely notice of the lawsuit or action to BGM and to cooperate with BGM in the defense of the lawsuit or
action, at BGM’s expense. 
 10.2 Indemnification by LabCorp. LabCorp agrees to indemnify, defend, and hold harmless
BGM, its Affiliates, and their respective employees, officers, directors, agents, successors, and assigns from and against any and all liabilities, obligations, losses, fines, costs, penalties, assessments, deficiencies, demands, actions, suits,
proceedings, judgments, expenses or damages of any nature (including without limitation attorneys’ fees) resulting from claims of third parties arising from or relating to (i) any breach of this Agreement by LabCorp (including without
limitation breach of any representations, warranties, covenants or obligations of LabCorp herein), (ii) any negligence or intentionally harmful misconduct of LabCorp, (iii) any misrepresentations made by LabCorp’s field
representatives or other employees or agents to third parties concerning the Test or Testing Services, or (iv) LabCorp and/or its Affiliates’ improper handling, storage or use of any Manual Test Kits or any incorrect reporting of results
from the performance of Manual Tests. However, the foregoing rights to indemnity shall not apply to the extent that such claim results from BGM’s negligence or intentionally harmful misconduct or BGM’s breach of this Agreement. In the
event of a lawsuit or other action in connection with which BGM is seeking indemnification from LabCorp hereunder, BGM agrees to give timely notice of the lawsuit or action to LabCorp and to cooperate with LabCorp in the defense of the lawsuit or
action, at LabCorp’s expense. 
 10.3 Warranty Disclaimer. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS AGREEMENT,
NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
 10.4 Limited Liability. NOTWITHSTANDING ANYTHING TO THE CONTRARY
IN THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS AFFILIATES FOR ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS OR LOST REVENUES, EXCEPT FOR
(A) DAMAGES INCLUDED IN THIRD PARTY CLAIMS FOR WHICH A PARTY IS ENTITLED TO INDEMNIFICATION FROM THE OTHER PARTY, OR (B) DAMAGES ARISING FROM INTENTIONAL MISCONDUCT OR GROSS NEGLIGENCE OF THE OTHER PARTY. 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

16 

 11. Intellectual Property Protection. 

11.1 Issuance and Maintenance of Patents. During the Semi-Exclusive Period, BGM agrees that it shall prosecute all U.S. patent
applications within the Licensed Technology in good faith and in accordance with the rules of the U.S. Patent and Trademark Office and use commercially reasonable efforts to obtain valid, issued patents based on such applications. During the
Semi-Exclusive Period, BGM shall submit all filings, make all payments, and take all other actions necessary to maintain all patents within the Licensed Technology as valid, in force and in good standing for the longest possible duration with the
U.S. Patent and Trademark Office (at its own expense). In addition, BGM agrees to provide general updates on a regular basis as to any filings made with, or notices received from, the U.S. Patent and Trademark Office or corresponding offices of
other countries with respect to the patents included within the Licensed Technology. 
 11.2 Enforcement of Rights.
During the Semi-Exclusive Period, BGM agrees that it shall, at its own expense, use commercially reasonable efforts to enforce its rights with respect to any infringement in the U.S. by a third party of any of the Licensed Technology through the
performance of Manual Tests. Without limiting the foregoing, in the event BGM is unsuccessful in persuading an alleged infringer to desist and fails to have initiated and diligently pursue an infringement suit within a reasonable time (not to exceed
four (4) months) after BGM first becomes aware of the basis for such suit, BGM shall grant LabCorp and its Affiliates the right to file suit on its behalf and BGM agrees to cooperate and provide reasonable assistance to LabCorp and its
Affiliates in connection with such suit. LabCorp and its Affiliates shall have the right to any recovery or damages obtained as a result of a suit brought by LabCorp and its Affiliates (whether by settlement, judgment or otherwise). To the extent
any infringement by a third party relates to any intellectual property licensed under the ACS In-License Agreement, BGM agrees to use reasonable efforts to obtain the consent of the other parties to the ACS In-License Agreement to allow LabCorp and
its Affiliates to file suit and retain any recovery or damages as described above. 
 11.3 Notice of Infringement. BGM
shall notify LabCorp immediately if it becomes aware of (i) any infringement by a third party of any patent covered by the Licensed Technology through the performance of Manual Tests during the Term, or (ii) any infringement of any patent
of a third party pursuant to the activities contemplated by this Agreement. 
 12. Insurance. BGM hereby represents that it is currently
maintaining, and BGM agrees to continue to maintain, at its sole expense, during the term of this Agreement, a policy of comprehensive general liability insurance with bodily injury, death, and property damage limits of [***] Dollars ($[***]) per
occurrence and [***] Dollars ($[***]) in the aggregate, including product and contractual liability coverage and such additional provisions as LabCorp may reasonably require. Each such insurance policy shall include a provision naming LabCorp as an

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

17 

 
additional insured and a provision providing that thirty (30) days’ written notice shall be given to LabCorp before cancellation, cessation or material modification of coverage. BGM
further agrees that these insurance requirements represent the minimum coverage BGM is required to carry and BGM shall remain liable for all liabilities in excess of such insurance which may arise for any reason. In the event that BGM elects
“claims made” coverage, BGM agrees that it shall either maintain continuous “claims made” coverage thereafter for a period of [***] ([***]) years or secure a [***] ([***]) year “tail” policy. 

13. Audits; Reviews. 

13.1 Rebates and MFN. LabCorp may engage, at its own cost, an independent certified public accounting firm reasonably acceptable
to BGM to verify LabCorp’s entitlement to any Rebates under Section 5.1 or the Manual Test Kit pricing offered by BGM to third parties for purposes of Section 4.2.b., and BGM will grant such firm access to BGM’s applicable
records relating to the foregoing subject to customary obligations of confidentiality. LabCorp will bear the cost of such audit unless the audit reveals that BGM’s failed to pay Rebates owed to LabCorp under Section 5.1 in an amount
exceeding [***] percent ([***]%) of the Rebates paid or failed to offer a more favorable Manual Test Kit price to LabCorp under Section 4.2.b., in which case BGM shall bear the costs associated with the audit. 

13.2 Facilities. LabCorp or its authorized representative shall have the right, upon [***] ([***]) business days advance notice to
BGM, to conduct audits of BGM’s facilities used to produce the Manual Test Kits to ensure compliance with the terms of this Agreement, but no more than [***] annually, and BGM shall cause its CMOs to grant such rights to LabCorp. BGM shall
grant or arrange with its CMOs to grant LabCorp, upon LabCorp’s request, access to such facilities during regular business hours for the purpose of conducting the compliance audit. LabCorp shall not unreasonably interfere with business
activities at these facilities while conducting the compliance audit. LabCorp will bear the cost of such audit unless a material breach is revealed in which case BGM shall bear the costs associated with the audit. 

13.3 Regulatory Authorities. BGM agrees to make its records and facilities available to the FDA or other Regulatory Authorities as
required by law or as requested for purposes of obtaining regulatory approval, clearance or other authorization for LabCorp’s testing services using the Manual Test Kits. 

13.4 Performance Reviews. 

a. Quarterly Reviews. BGM and LabCorp will conduct quarterly business reviews to discuss technical performance of all Manual Test
Kits and services included in this Agreement. In the event that technical problems are identified, LabCorp will notify BGM of the problem by telephone or electronic communication, and BGM will, within the course of five (5) days, identify an
action plan to correct the problem and deliver this, in writing, to LabCorp. 
 b. Performance Levels. LabCorp shall use
reasonably necessary measurements, monitoring tools and procedures required to measure and report the performance 
  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

18 

 
of the Services against the applicable performance standards outlined in Exhibit D. Such measurements shall permit reporting at a level of detail sufficient to verify compliance with such
performance standards and shall be subject to reasonable audit by BGM. LabCorp shall provide reports to BGM regarding BGM’s performance against applicable service levels and such documentation and other information with respect to its tools and
procedures as may be reasonably requested by BGM from time to time to verify that BGM’s performance is in compliance with the terms and conditions of this Agreement. LabCorp will generate a scorecard measuring BGM’s performance levels on a
quarterly basis. BGM must achieve an overall performance level of at least [***] percent ([***]%). In the event that BGM does not meet such performance standards, a penalty of [***] Dollars ($[***]) per quarter shall be paid to LabCorp by BGM.
Payments shall be paid within [***] ([***]) [***] of the end of the reporting quarter. In no event will the performance penalty per year exceed [***] Dollars ($[***]). 

14. Miscellaneous. 

14.1 Governing Law. This Agreement and the rights and obligations of the parties hereunder shall be governed by and construed in
accordance with the laws of the State of North Carolina, without regard to its conflicts of laws principles. 
 14.2 Benefit;
Assignment. The rights, duties, and obligations of the parties under this Agreement shall inure to the benefit and shall be binding upon their respective successors and permitted assigns. Neither this Agreement nor the respective rights, duties,
obligations, and responsibilities of either party under this Agreement may be assigned, subcontracted or otherwise transferred, in whole or in part, to any other Entity without the prior written consent of the other party, which consent shall not be
unreasonably withheld; provided, however, that without such consent (i) BGM shall have the right to have Manual Test Kits manufactured by a CMO (subject to the last sentence of this Section 14.2), and (ii) either party
may assign this Agreement in whole, but not in part, to any purchaser of all or substantially all of its assets to which this Agreement relates, or to any successor corporation resulting from a Change of Control. In the event a party subcontracts
its obligations under this Agreement to another party, such party shall be responsible for any breach of this Agreement by its subcontractor. 

14.3 Relationship. The relationship between BGM and LabCorp is solely that of seller/licensor, on the one hand, and
buyer/licensee, on the other hand, and nothing in this Agreement shall constitute either party as the agent, partner or legal representative of the other party for any purpose whatsoever; nor shall either party hold itself out as such. Neither party
shall have any authority to bind or commit the other party in any manner or for any purpose. 
 14.4 Notices. Any notice,
request or communication given, made or sent pursuant to the terms of this Agreement shall be made in writing and shall be deemed duly given: (i) on the day delivered personally, (ii) three (3) days after being sent registered or
certified mail, return receipt requested, or (iii) one day after the date communicated via facsimile (with the original being sent the same day by registered or certified mail, return receipt requested) to the other party at the following
addresses and numbers (or to such other addresses and numbers as either party hereto may hereafter designate in writing): 
  

			
	BGM	  	 LabCorp

		
	 BG Medicine, Inc.
 Attn:
President
 610N Lincoln Street

Waltham, MA 02451
 Fax:
(781) 895-1119
	  	 Laboratory Corporation of America Holdings

Attn: General Counsel

531 South Spring Street

Burlington, NC 27215

Fax: (336) 226-3835

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

19 

 14.5 Use of LabCorp’s Name. BGM acknowledges that LabCorp has a proprietary
interest in its legal and business name and reputation. Therefore, BGM agrees that it shall not use LabCorp’s name nor shall BGM mention or describe this Agreement or its relationship with LabCorp in any press release, advertising, marketing,
and promotional materials or other publications or materials without first obtaining the prior written approval of LabCorp, except as required by law (and in cases required by law, BGM agrees to provide prior written notice to LabCorp and an
opportunity to provide input to the extent possible). 
 14.6 Change in Law. The terms of this Agreement are intended to
be in compliance with all federal, state and local statutes, regulations and ordinances applicable on the Effective Date. The parties agree to execute amendments as may be necessary for the continuing compliance with the aforementioned applicable
laws, as additional regulations are promulgated or become final and effective. 
 14.7 Severability; Headings; Counterparts;
Amendment; Waiver; Entire Agreement. If any term or provision of this Agreement shall be held invalid or unenforceable, the remaining items hereof shall not be affected, but shall be valid and enforced to the fullest extent permitted by law. The
headings used in this Agreement are intended for guidance only and shall not be considered part of the written understanding between the parties hereto. This Agreement may be executed in counterparts in order to provide each party with a
fully-executed original hereof. Except as otherwise provided herein, this Agreement may not be changed, modified or amended except by an agreement in writing signed by both parties. The waiver by any party to this Agreement of any breach or
violation of any provisions of this Agreement by any other party hereto shall not operate as a waiver of any other or subsequent breach. All Exhibits attached hereto are hereby incorporated by reference. This Agreement and its Exhibits reflects the
complete understanding of the parties and constitutes their entire agreement, superseding all prior negotiations, representations, agreements, understandings, and statements regarding its subject matter. 

14.8 Force Majeure. Neither party shall be liable for loss, damage, detention or delay resulting from any cause whatsoever beyond
its reasonable control or resulting from a force majeure, including, without limitation, fire, flood, strike, lockout, civil or military authority, 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

20 

 
insurrection, war, or embargo, and delivery dates shall be extended to the extent of any delays resulting from the foregoing or similar causes. The party so affected shall give prompt notice to
the other party of such cause, and shall take whatever reasonable steps are necessary to relieve the effect of such cause as rapidly as reasonably possible. The party giving such notice shall be excused from such of its obligations hereunder for so
long as it is so disabled; provided, however, that such affected party commences and continues to take reasonable and diligent actions to cure such cause. Notwithstanding the foregoing, nothing in this Section 14.8 shall excuse or suspend the
obligation to make any payment due hereunder in the manner and at the time provided. 
 IN WITNESS WHEREOF, LabCorp and BGM have
caused this Agreement to be executed by their duly authorized officer as of the Effective Date. 
  

									
	BG Medicine, Inc.	 		 	Laboratory Corporation of America Holdings
					
	By:	 	 /s/ Pieter Muntendam
	 		 	By:	 	 /s/ David P. King

									
					
	Printed Name:	 	 Pieter Muntendam
	 		 	Printed Name:	 	 David P. King

									
					
	Title:	 	 President and CEO
	 		 	Title:	 	 CEO

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

21 

 Exhibit A 

Licensed Patents 

BG MEDICINE INC. PATENTS and PATENT APPLICATIONS RELATING TO GALECTIN-3 - 

Status on April 16, 2010 
  

											
	 PATENT
TITLE
	  	 DOCKET

No.
	  	 COUNTRY
	  	 SERIAL or
PATENT No.
	  	 FILING
DATE
	  	 STATUS

	[***]	  	[***]	  	 Europe

PCT
 US

Canada
 Australia

 Australia

Japan

China

India

Europe
 Hong Kong

	  	[***]	  	[***]	  	 Expired

Expired
 Pending

 Pending

Allowed 08 Jul 2009

Pending
 Pending

 Pending

Pending
 Pending

 Pending

	[***]	  	[***]	  	 US Provisional

US

PCT
	  	[***]	  	[***]	  	 Expired

Pending
 Pending

	[***]	  	[***]	  	 US Provisional

PCT
 US

Australia
 Canada

 Europe

Japan
	  	[***]	  	[***]	  	 Expired

Expired
 Pending

 Pending

Pending
 Pending

 Pending

	[***]	  	[***]	  	US Provisional	  	[***]	  	[***]	  	Pending
	[***]	  	[***]	  	US Provisional	  	[***]	  	[***]	  	Pending

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

22 

 Exhibit B 

Manual Test Kit Description 

[Actual package insert to be included upon FDA approval of the Manual Test] 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

23 

 Exhibit C 

[***] Which Are Not Restricted Licensees 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

[***] 
 [***] 

Note: In the event any Entity listed above on this Exhibit (as of the Effective Date or subsequently added) or its Affiliate enters into an
M&A Transaction (as defined in Section 3.11) with an Entity that was a Restricted Licensee prior to such transaction, then such Entity listed above shall automatically be deemed to be removed from this Exhibit. 

 

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

24 

 Exhibit D 

Performance Levels 
 BG
Medicine Scorecard 
 Date: 
  

									
	 [***]%
	  	 On time delivery
	  	Expected	  	Actual %	  	Score
	 [***]%
	  	 On-time Shipments - Delivery on the requested arrival date (RAD)
	  	[***]%	  		  	
		  	 Late Shipments - Delivery after RAD
	  		  		  	
		  	 Early Shipments - Delivery more than 1 business day prior to RAD
	  		  		  	
	 [***]%
	  	 Order Accuracy - BGM provides the ordered product
	  	[***]%	  		  	
	 [***]%
	  	 Returns - BGM provides quality products without defects
	  	[***]%	  		  	
					
	 [***]%
	  	 Communications
	  	Expected	  	Actual %	  	Score
	 [***]%
	  	 POs are acknowledged within 24 hours of receipt
	  	[***]%	  		  	
	 [***]%
	  	 PO Acknowledgments are correct based on price, quantity, and item
	  	[***]%	  		  	
	 [***]%
	  	 ASNs are distributed within 12 hours of shipment (when available)
	  	[***]%	  		  	
	 [***]%
	  	 ASNs are correct based on ship date, tracking information, PO, item, lot, and quantity (when available)
	  	[***]%	  		  	
	 [***]%
	  	 Pricing changes are communicated 20 business days in advance and include an updated pricing file
	  	Conforming	  		  	
	 [***]%
	  	 Invoice contains the correct PO, contract price, item, and quantity
	  	[***]%	  		  	

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

25 

									
	 [***]%
	  	 Communications Methods
	  	Expected	  	Actual %	  	Score
		  	 EDI
	  		  		  	
	 [***]%
	  	 Accepts EDI POs
	  		  		  	
	[***]%	  	Acknowledges POs via EDI	  		  		  	
	[***]%	  	Provides ASNs EDI (when available)	  		  		  	
	[***]%	  	Invoices EDI	  		  		  	
	OR	  	Internet Based 	  		  		  	
	[***]%	  	Accepts POs via eSupplier	  		  		  	
	[***]%	  	Acknowledges POs via eSupplier	  		  		  	
	[***]%	  	Provides ASNs via eSupplier (when available)	  		  		  	
	[***]%	  	Invoices via eSettlements	  		  		  	
					
	 [***]%
	  	 Customer Service
	  	Expected	  	Actual %	  	Score
	 [***]%
	  	 Responds quickly and thoroughly to requests, written and verbal
	  	Meets
Expectations	  		  	
	[***]%	  	Provides dedicated account manager	  	Yes	  		  	
	[***]%	  	Provides dedicated purchasing contact	  	Yes	  		  	
					
	 	  	 	  	Expected	  	 	  	Score
		  	Score	  	[***]%	  		  	[***]%

  

 Portions of this Exhibit were omitted and have been filed separately with the Secretary of
the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended. 

26Form of Indemnification Agreement

 Exhibit 10.21 

INDEMNIFICATION AGREEMENT 

THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this
     day of             , 20    , by and between BG MEDICINE, INC., a Delaware corporation (the
“Corporation”), and                      (“Agent”). 

RECITALS 

WHEREAS, Agent performs a valuable service to the Corporation in his capacity as [a director and/or an officer] of the
Corporation; 
 WHEREAS, the Corporation has adopted provisions providing for indemnification of directors and officers
included in its Restated Certificate of Incorporation (the “Charter”) and its bylaws (the “Bylaws”) providing for the indemnification of the directors, officers, employees and other agents of the
Corporation, including persons serving at the request of the Corporation in such capacities with other corporations or enterprises, as authorized by the Delaware General Corporation Law, as amended (the “DGCL”); 

WHEREAS, the Charter, the Bylaws and the DGCL, by their non-exclusive nature, permit contracts between the Corporation and its
directors, officers, employees and other agents with respect to indemnification of such persons; 
 WHEREAS, in
recognition of Agent’s need for (a) substantial protection against personal liability based on Agent’s reliance on the Charter and the Bylaws, and (b) specific contractual assurance that the protection provided in the Charter and
the Bylaws will be available to Agent (regardless of, among other things, any amendment to or revocation of the Charter and/or the Bylaws, any change in the composition of the Corporation’s board of directors or a change in control of the
Corporation); and 
 WHEREAS, in order to induce Agent to [continue to] serve as [a director/an officer] of the
Corporation, the Corporation has determined and agreed to enter into this Agreement with Agent. 
 NOW, THEREFORE, in
consideration of Agent’s service as [a director and/or an officer] of the Corporation following the date hereof, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Corporation and
Agent hereby agree as follows: 
 1. Services to the Corporation. Agent will serve, at the will of the Corporation or
under separate contract, if any such contract exists, as [a director/an officer] of the Corporation or as a director, officer or other fiduciary of an affiliate of the Corporation (including any employee benefit plan of the Corporation) faithfully
and to the best of his ability so long as he [is duly elected and qualified in accordance with the provisions of the Bylaws or other applicable charter documents/is a duly appointed officer] of the Corporation or such affiliate; provided,
however, that Agent may at any time and for any reason resign from such position (subject to any contractual obligation that Agent may have assumed apart from this Agreement) and that the Corporation or any affiliate shall have no obligation
under this Agreement to continue Agent in any such position. 
 2. Indemnity of Agent. The Corporation agrees to hold
harmless and indemnify Agent to the fullest extent authorized or permitted by the provisions of the Charter, the Bylaws and the 

 
DGCL, as the same may be amended from time to time (but, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than the Charter, the Bylaws or
the DGCL permitted prior to adoption of such amendment). 
 3. Additional Indemnity. In addition to and not in limitation
of the indemnification otherwise provided for herein, and subject only to the exclusions set forth in Section 4 hereof, the Corporation further agrees to hold harmless and indemnify Agent: 

(a) against any and all expenses (including attorneys’ fees), witness fees, damages, judgments, fines and amounts paid in
settlement and any other amounts that Agent becomes legally obligated to pay (including any federal, state or local taxes imposed on Agent as a result of receipt of reimbursements or advances of expenses under this Agreement) because of any claim or
claims made against or by him in connection with any threatened, pending or completed action, suit or proceeding, including any appeal and the premium, security for, and other costs relating to any costs bond, supersedes bond, or other appeal bond
or its equivalent, whether civil, criminal, arbitrational, administrative or investigative, whether formal or informal (including an action by or in the right of the Corporation), to which Agent is, was or at any time becomes a party or a witness,
or is threatened to be made a party or a witness, by reason of the fact that Agent is, was or at any time becomes a director, officer, employee or other agent of the Corporation, or is or was serving or at any time serves at the request of the
Corporation as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise; and 

(b) otherwise to the fullest extent as may be provided to Agent by the Corporation under the non-exclusivity provisions of the
DGCL, the Charter and the Bylaws. 
 4. Limitations on Additional Indemnity. No indemnity pursuant to Section 3
hereof shall be paid by the Corporation: 
 (a) on account of any claim or proceeding against Agent for an accounting of
profits made from the purchase or sale by Agent of securities of the Corporation pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934, as heretofore or hereafter amended (the “Exchange
Act”), or similar provisions of any federal, state or local law, provided, however, if and when Agent ultimately establishes in any such proceeding that no recovery of profits from Agent is permitted under Section 16(b) of
the Exchange Act or such similar provision of any similar federal, state or local law, then, notwithstanding anything to the contrary provided in this Section 4(a), indemnification pursuant to this Agreement shall then be permitted; 

(b) on account of Agent’s conduct that is established by a final judgment as knowingly fraudulent or deliberately dishonest
or that constituted willful misconduct; 
 (c) on account of Agent’s conduct that is established by a final judgment
as constituting a breach of Agent’s duty of loyalty to the Corporation or resulting in any personal profit or advantage to which Agent was not legally entitled; 

(d) for which payment is actually made to Agent under a valid and collectible insurance policy or under a valid and enforceable
indemnity clause, bylaw or agreement, except in respect of any excess beyond payment under such insurance, clause, bylaw or agreement; 
  

 2 

 (e) if indemnification is not lawful (and, in this respect, both the Corporation and
Agent have been advised that the Securities and Exchange Commission believes that indemnification for liabilities arising under the federal securities laws is against public policy and is, therefore, unenforceable and that claims for indemnification
should be submitted to appropriate courts for adjudication); or 
 (f) in connection with any proceeding (or part
thereof) initiated by Agent, or any proceeding by Agent against the Corporation or its directors, officers, employees or other agents, unless (i) such indemnification is expressly required to be made by law, (ii) the proceeding was
authorized by the board of directors of the Corporation, (iii) such indemnification is provided by the Corporation, in its sole discretion, pursuant to the powers vested in the Corporation under the DGCL, or (iv) the proceeding is
initiated pursuant to Section 11 hereof. 
 5. Continuation of Indemnity. All agreements and obligations of the
Corporation contained herein shall continue during the period Agent is a director, officer, employee or other agent of the Corporation (or is or was serving at the request of the Corporation as a director, officer, employee or other agent of another
corporation, partnership, joint venture, trust, employee benefit plan or other enterprise) and shall continue thereafter so long as Agent shall be subject to any possible claim or threatened, pending or completed action, suit or proceeding, whether
civil, criminal, arbitrational, administrative or investigative, by reason of the fact that Agent was serving in the capacity referred to herein. 

6. Partial Indemnification. Agent shall be entitled under this Agreement to indemnification by the Corporation for a portion of
the expenses (including attorneys’ fees), witness fees, damages, judgments, fines and amounts paid in settlement and any other amounts that Agent becomes legally obligated to pay in connection with any action, suit or proceeding referred to in
Section 3 hereof even if not entitled hereunder to indemnification for the total amount thereof, and the Corporation shall indemnify Agent for the portion thereof to which Agent is entitled. 

7. Notification and Defense of Claim. As soon as practicable, and in any event, not later than thirty (30) days after Agent
becomes aware, by written or other overt communication, of any pending or threatened litigation, claim or assessment, Agent will, if a claim in respect thereof is to be made against the Corporation under this Agreement, notify the Corporation of
such pending or threatened litigation, claim or assessment; but the omission so to notify the Corporation will not relieve it from any liability which it may have to Agent otherwise than under this Agreement. With respect to any such pending or
threatened litigation, claim or assessment as to which Agent notifies the Corporation of the commencement thereof: 
 (a)
the Corporation will be entitled to participate therein at its own expense; 
 (b) except as otherwise provided
below, the Corporation may, at its option and jointly with any other indemnifying party similarly notified and electing to assume such defense, assume the defense thereof, with counsel reasonably satisfactory to Agent. After notice from the
Corporation to Agent of its election to assume the defense thereof, the Corporation will not be liable to Agent under this Agreement for any legal or other expenses subsequently incurred by Agent in connection with the defense thereof except for
reasonable costs of investigation or otherwise as provided below. Agent shall have the right to employ separate counsel in such action, suit or proceeding but the fees and expenses of such counsel incurred after notice from the Corporation of its
assumption of the defense thereof shall be at the expense of Agent unless (i) the employment of 
  

 3 

 
counsel by Agent has been authorized by the Corporation, (ii) Agent shall have reasonably concluded, and so notified the Corporation, that there is an actual conflict of interest between the
Corporation and Agent in the conduct of the defense of such action, or (iii) the Corporation shall not in fact have employed counsel to assume the defense of Agent in connection with such action, in any of such cases the fees and expenses of
Agent’s separate counsel shall be at the expense of the Corporation. The Corporation shall not be entitled to assume the defense of any action, suit or proceeding brought by or on behalf of the Corporation or as to which Agent shall have made
the conclusion provided for in clause (ii) above; and 
 (c) the Corporation shall not be liable to indemnify Agent
under this Agreement for any amounts paid in settlement of any action or claim effected without its written consent, which shall not be unreasonably withheld or delayed. The Corporation shall be permitted to settle any action or claim except that it
shall not settle any action or claim in any manner which would impose any penalty or limitation on Agent without Agent’s written consent, which may be given or withheld in Agent’s sole discretion. 

8. Expenses. The Corporation shall advance, prior to the final disposition of any proceeding, promptly following request therefor,
all expenses incurred by Agent in connection with such proceeding upon the Corporation’s receipt of an undertaking by or on behalf of Agent to repay said amounts if it shall be determined ultimately that Agent is not entitled to be indemnified
under the provisions of this Agreement, the Charter, the Bylaws, the DGCL or otherwise. Such undertaking shall be accepted by the Corporation without regard to the financial ability of Agent to make such repayment. Without limiting the foregoing, if
any action, suit or proceeding is disposed of on the merits or otherwise (including a disposition without prejudice), without (i) the final disposition being adverse to Agent, (ii) a final adjudication that Agent was liable to the
Corporation, (iii) a plea of guilty (iv) a final adjudication that Agent did not act in good faith, and in a manner he reasonably believed to be in or not opposed to the best interests of the Corporation, or (v) with respect to any
criminal proceeding, a final adjudication that Agent had reasonable cause to believe his conduct was unlawful, Agent shall be considered for the purposes hereof to have been wholly successful with respect thereto. 

9. Information Sharing. To the extent that the Corporation receives a request or requests from a governmental third party or other
licensing or regulating organization (the “Requesting Agency”), whether formal or informal, to produce documentation or other information concerning an investigation, whether formal or informal, being conducted by the
Requesting Agency, and such investigation is reasonably likely to include review of any actions or failures to act by Agent, the Corporation shall promptly give notice to Agent of said request or requests and any subsequent request. In addition, the
Corporation shall provide Agent with a copy of any and all information or documentation that the Corporation shall provide to the Requesting Agency. 

10. No Imputation. The knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Corporation
or the Corporation itself shall not be imputed to Agent for purposes of determining any rights under this Agreement. 
 11.
Enforcement. Any right to indemnification or advances granted by this Agreement to Agent shall be enforceable by or on behalf of Agent in any court of competent jurisdiction if (i) the claim for indemnification or advances is denied, in
whole or in part, or (ii) no disposition of such claim is made within ninety (90) days of request therefor. Agent, in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting
his claim. 
  

 4 

 
It shall be a defense to any action for which a claim for indemnification is made under Section 3 hereof (other than an action brought to enforce a claim for advance or reimbursement of
expenses under this Agreement, provided that the required undertaking has been tendered to the Corporation) that Agent is not entitled to indemnification because of the limitations set forth in Section 4 hereof. Neither the failure of
the Corporation (including its board of directors or its stockholders) to have made a determination prior to the commencement of such enforcement action that indemnification of Agent is proper in the circumstances, nor an actual determination by the
Corporation (including its board of directors or its stockholders) that such indemnification is improper shall be a defense to the action or create a presumption that Agent is not entitled to indemnification under this Agreement or otherwise.

 12. Subrogation. In the event of payment under this Agreement, the Corporation shall be subrogated to the extent of
such payment to all of the rights of recovery of Agent, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Corporation effectively to bring suit to enforce such rights.

 13. Non-Exclusivity of Rights. The rights conferred on Agent by this Agreement shall not be exclusive of any other
right which Agent may have or hereafter acquire under any statute, provision of the Charter or Bylaws, agreement, vote of stockholders or directors, or otherwise, both as to action in his official capacity and as to action in another capacity while
holding office. 
 14. Survival of Rights. 

(a) The rights conferred on Agent by this Agreement shall continue after Agent has ceased to be a director, officer, employee or
other agent of the Corporation or to serve at the request of the Corporation as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, and shall inure to the
benefit of Agent’s heirs, executors and administrators. 
 (b) The Corporation shall require any successor (whether
direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of the Corporation, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the
Corporation would be required to perform if no such succession had taken place. 
 15. Separability. Each of the
provisions of this Agreement is a separate and distinct agreement and independent of the others, so that if any provision hereof shall be held to be invalid or unenforceable for any reason, such invalidity or unenforceability shall not affect the
validity or enforceability of the other provisions hereof. Furthermore, if this Agreement shall be invalidated in its entirety on any ground, then the Corporation shall nevertheless indemnify Agent to the fullest extent provided by the Charter, the
Bylaws, the DGCL or any other applicable law. 
 16. Governing Law. This Agreement shall be governed by, and construed
and enforced in accordance with, the laws of the State of Delaware, without regard to its principles of conflicts of laws. The Corporation and Agent hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of
or in connection with this Agreement may be brought in the Delaware Court of Chancery, (ii) consent to submit to the jurisdiction of the Delaware Court of Chancery for purposes of any action or proceeding arising out of or in connection with
this Agreement, (iii) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court of Chancery, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in
the Delaware Court of Chancery has been brought in an improper or inconvenient forum. 
  

 5 

 17. Amendment and Termination. No amendment, modification, termination or
cancellation of this Agreement shall be effective unless in writing signed by both parties hereto. 
 18. Identical
Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute but one and the same Agreement. Only one such counterpart need
be produced to evidence the existence of this Agreement. 
 19. Notices. All notices, requests, demands and other
communications hereunder shall be in writing and shall be deemed to have been duly given (i) upon delivery if delivered by hand to the party to whom such communication was directed or (ii) upon the third business day after the date on
which such communication was mailed if mailed by certified or registered mail with postage prepaid: 
  

	 	(a)	If to Agent, at the address indicated on the signature page hereof. 

 

	 	(b)	If to the Corporation, to: 

BG Medicine, Inc. 

610 Lincoln Street North 

Waltham, MA 02451 

Attention: Chief Executive Officer 

or to such other address as may have been furnished to Agent by the Corporation. 

20. Headings. The headings of the sections of this Agreement are inserted for convenience only and shall not be deemed to
constitute part of this Agreement or to affect the construction hereof. 
 [Remainder of page intentionally left blank.]

  

 6 

 IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement
on and as of the day and year first above written. 
  

			
	BG MEDICINE, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	
	
	AGENT
	
	  

	[Insert Name of Agent]
	
	Address:
	  

	  

 

 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00178-of-00352.parquet"}]]